Methylation Profiling More Accurately Predicts Recurrence Risk in Meningiomas

This 10-minute conference talk from the Cancer Genomics Consortium (CGC) 2024 Annual Meeting explores how methylation profiling provides more accurate prediction of recurrence risk in meningiomas compared to traditional WHO grading criteria. Presented by Lucas Santana dos Santos, learn about advanced genomic approaches that could improve diagnostic accuracy and treatment planning for meningioma patients. Discover how the CGC, an organization of clinical cytogeneticists, molecular geneticists, and molecular pathologists, works to promote best practices in clinical cancer genomics with the vision of ensuring all cancer patients receive accurate genomic diagnoses to guide appropriate therapy.